Solifenacin – first experiences in overactive bladder treatment

Grzegorz Surkont; Edyta Wlaźlak; Jacek Suzin

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2006
vol. 5

Send email

Copy url:

abstract:

Solifenacin – first experiences in overactive bladder treatment

Grzegorz Surkont

,

Edyta Wlaźlak

,

Jacek Suzin

Prz Menopauz 2006; 1: 43–46

Online publish date: 2006/02/17

View full text Get citation

Aim of the study:
In the article we presented first our experiences with ovaractive bladder (OAB) treatment with the use of new antimuscarinic drug Vesicare (Astellas).
Material and methods:
In the analysis we included first 20 patients aged 57-81 with OAB complaints. We analised first two months of treatment with solifenacin used in oral tablets in dose 5 mg given once daily. Patients were evaluted before and after 8 weeks of treatment. In the study we evaluated the efficacy of treatment and patient’s compliance.
Conclusions:
Solifenacin in 5 mg dose is efficient in OAB treatment. It is well tolerated. Side effects on low level are rare. These conclusions are preliminary. More detailed analysis will be possible after long-time evaluations on bigger numbers of patients.

keywords:

Solifenacin – first experiences in overactive bladder treatment

Grzegorz Surkont , Edyta Wlaźlak , Jacek Suzin

overactive bladder, OAB, urinary incontinence, solifenacin, non-operative treatment

Grzegorz Surkont

,

Edyta Wlaźlak

,

Jacek Suzin